Use of Dextran 40 After Pancreas Transplant May Reduce Early Inflammation and Significant Bleeding Compared to a Heparin-Based Protocol.

BACKGROUND

Dextran 40 (D40) is a synthetic colloid with anticoagulant properties that is used instead of heparin after pancreas transplantation; however, there is a lack of evidence on which is more effective. Graft thrombosis and pancreatitis, which may be mediated through microthrombosis or macrothrombosis within the graft, remain significant complications after pancreas transplantation. We hypothesized that D40 reduces inflammation through its antithrombotic promicrocirculatory effects. We evaluated D40 compared to a heparin-based protocol by comparing postoperative complications and post-transplant levels of inflammation.

MATERIALS AND METHODS

Data were collected retrospectively for pancreas transplant patients between December 2009 and August 2018. A total of 26 patients had been treated with the pre-dextran protocol and 37 had received D40. Postoperative complications and inflammatory markers (white cell count [WCC], C-reactive protein [CRP], and amylase) on postoperative days 1, 2, 3, and 7 were compared between groups. Potential confounders were also recorded.

RESULTS

Patients in the D40 group had similar thrombosis rates but were less likely to have had graft loss as a result of thrombosis or substantial postoperative bleeding compared to the heparin-based protocol. The group who received D40 had significantly lower CRP and WCC on days 2, 3, and 7. The differences on days 3 and 7 remained when the results were adjusted for the significant confounders of cold ischemic time and donor age.

CONCLUSIONS

D40 appears to be as effective as intravenous heparin at preventing graft thrombosis after pancreas transplant and to confer a reduced risk for bleeding. It may also reduce postoperative inflammatory processes, leading to reduced graft pancreatitis.